The challenge of HIV treatment in an era of polypharmacy

The availability of potent antiretroviral therapy has transformed HIV infection into a chronic disease such that people living with HIV (PLWH) have a near normal life expectancy. However, there are continuing challenges in managing HIV infection, particularly in older patients, who often experience age‐related comorbidities resulting in complex polypharmacy and an increased risk for drug‐drug interactions. Furthermore, age‐related physiological changes may affect the pharmacokinetics and pharmacodynamics of both antiretrovirals and comedications thereby predisposing elderly to adverse drug reactions. This review provides an overview of the therapeutic challenges when treating elderly PLWH (i.e. >65 years). Particular emphasis is placed on drug‐drug interactions and other common prescribing issues (i.e. inappropriate drug use, prescribing cascade, drug‐disease interaction) encountered in elderly PLWH.

[1]  C. Marzolini,et al.  Polypharmacy and drug-drug interactions in HIV-infected subjects in the region of Madrid, Spain: a population-based study. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Samah J. Jarad,et al.  Polypharmacy, hazardous alcohol and illicit substance use and serious falls among PLWH and uninfected comparators. , 2019, Journal of acquired immune deficiency syndromes.

[3]  J. Parienti,et al.  Cushing's syndrome due to interaction between ritonavir or cobicistat and corticosteroids: a case-control study in the French Pharmacovigilance Database. , 2019, The Journal of antimicrobial chemotherapy.

[4]  A. Winston,et al.  Risk factors and impact of patterns of co-occurring comorbidities in people living with HIV. , 2019, AIDS (London).

[5]  E. M. Kalmar,et al.  Getting older with HIV: increasing frequency of comorbidities and polypharmacy in Brazilian HIV patients. , 2019, AIDS research and human retroviruses.

[6]  F. Palella,et al.  Examination of Polypharmacy Trajectories Among HIV-Positive and HIV-Negative Men in an Ongoing Longitudinal Cohort from 2004 to 2016. , 2019, AIDS patient care and STDs.

[7]  C. Marzolini,et al.  Prescribing issues in elderly individuals living with HIV , 2019, Expert review of clinical pharmacology.

[8]  C. Flexner,et al.  Predicting Drug–Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling , 2019, The Journal of infectious diseases.

[9]  Marco Siccardi,et al.  A Comprehensive Framework for Physiologically‐Based Pharmacokinetic Modeling in Matlab , 2019, CPT: pharmacometrics & systems pharmacology.

[10]  K. Anastos,et al.  Non-HIV Comorbid Conditions and Polypharmacy Among People Living with HIV Age 65 or Older Compared with HIV-Negative Individuals Age 65 or Older in the United States: A Retrospective Claims-Based Analysis. , 2019, AIDS patient care and STDs.

[11]  E. Gardner,et al.  Risk and Cost Associated With Drug–Drug Interactions Among Aging HIV Patients Receiving Combined Antiretroviral Therapy in France , 2019, Open forum infectious diseases.

[12]  J. Velez,et al.  Non-AIDS-related comorbidities in people living with HIV-1 aged 50 years and older: The AGING POSITIVE study. , 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[13]  A. Winston,et al.  Polypharmacy and Drug–drug Interactions in Older and Younger People Living with HIV: The POPPY Study , 2019, Antiviral therapy.

[14]  A. Winston,et al.  Patterns of Co-occurring Comorbidities in People Living With HIV , 2018, Open forum infectious diseases.

[15]  A. Mocroft,et al.  Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort , 2018, AIDS.

[16]  C. Katlama,et al.  Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients , 2018, PloS one.

[17]  E. Clementi,et al.  Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice , 2018, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[18]  Ju-Young Shin,et al.  Assessment of Consistency of Drug Interaction Information in Drug Labels Among the United States, the United Kingdom, China, Japan, and Korea , 2018, Clinical pharmacology and therapeutics.

[19]  M. Battegay,et al.  Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes , 2018, Clinical Pharmacokinetics.

[20]  P. Neuvonen,et al.  Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel , 2018, Clinical pharmacology and therapeutics.

[21]  B. Clotet,et al.  Recurrent coronary disease in HIV‐infected patients: role of drug–drug interactions , 2018, British journal of clinical pharmacology.

[22]  M. Núñez-Núñez,et al.  Interacciones potenciales en una cohorte de pacientes VIH positivos de edad avanzada , 2018 .

[23]  C. Kerr 06 / SCREENING FOR SEXUAL HEALTH INFECTIONS INCLUDING CHLAMYDIA, GONORRHEA AND SYPHILIS IN ACCORDANCE WITH EUROPEAN AIDS CLINICAL SOCIETY (EACS) GUIDELINES , 2018 .

[24]  A. Kahn,et al.  Cancer Risk in Older Persons Living With Human Immunodeficiency Virus Infection in the United States , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  T. Naito,et al.  Comorbidities and the use of comedications in people living with HIV on antiretroviral therapy in Japan: a cross-sectional study using a hospital claims database , 2018, BMJ Open.

[26]  F. Stanaway,et al.  Polypharmacy among HIV positive older adults on anti-retroviral therapy attending an urban clinic in Uganda , 2018, BMC Geriatrics.

[27]  E. Sprinz,et al.  Comorbidity is more common and occurs earlier in persons living with HIV than in HIV-uninfected matched controls, aged 50 years and older: A cross-sectional study. , 2018, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[28]  M. Battegay,et al.  Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications , 2018, Antimicrobial Agents and Chemotherapy.

[29]  C. Mussi,et al.  The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 – 74 years and more than 75 years , 2018, BMC Geriatrics.

[30]  A. Taburet,et al.  Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review , 2018, British journal of clinical pharmacology.

[31]  A. Justice,et al.  Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals , 2018, AIDS.

[32]  A. Justice,et al.  Non antiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals. , 2018, AIDS.

[33]  D. Kuh,et al.  Associations Between Polypharmacy and Cognitive and Physical Capability: A British Birth Cohort Study , 2018, Journal of the American Geriatrics Society.

[34]  Y. Daali,et al.  Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites , 2018, Clinical Pharmacokinetics.

[35]  M. Shebley,et al.  Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model , 2018, Journal of Pharmacokinetics and Pharmacodynamics.

[36]  C. B. Hare,et al.  A Pharmacist‐Led Program to Evaluate and Reduce Polypharmacy and Potentially Inappropriate Prescribing in Older HIV‐Positive Patients , 2017, Pharmacotherapy.

[37]  A. d’Arminio Monforte,et al.  Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study , 2017, PloS one.

[38]  P. Reiss,et al.  Higher Prevalence and Faster Progression of Chronic Kidney Disease in Human Immunodeficiency Virus–Infected Middle-Aged Individuals Compared With Human Immunodeficiency Virus–Uninfected Controls , 2017, The Journal of infectious diseases.

[39]  J. George,et al.  Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran , 2017, Antimicrobial Agents and Chemotherapy.

[40]  L. Calza,et al.  Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV‐1 infection , 2017, HIV medicine.

[41]  W. Spreen,et al.  Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects , 2017, Antimicrobial Agents and Chemotherapy.

[42]  C. Katlama,et al.  Ageing with HIV: do comorbidities and polymedication drive treatment optimization? , 2017, HIV medicine.

[43]  C. Sabin,et al.  Epidemiology of ageing with HIV: what can we learn from cohorts? , 2017, AIDS.

[44]  J. Sterne,et al.  Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies , 2017, The lancet. HIV.

[45]  P. Rochon,et al.  The prescribing cascade revisited , 2017, The Lancet.

[46]  K. Gough,et al.  Extensive Bruising and Elevated Rivaroxaban Plasma Concentration in a Patient Receiving Cobicistat-Boosted Elvitegravir , 2017, The Annals of pharmacotherapy.

[47]  S. Walmsley,et al.  Increase in international normalized ratio after switching from atazanavir/ritonavir to darunavir/cobicistat in a patient on warfarin: boosters are not always equal. , 2017, AIDS.

[48]  A. Pottegård,et al.  Use of non-antiretroviral drugs among individuals with and without HIV-infection: a Danish nationwide study , 2017, Infectious diseases.

[49]  M. Zwahlen,et al.  Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population , 2016, AIDS.

[50]  R. Krishna,et al.  Effect of metal‐cation antacids on the pharmacokinetics of 1200 mg raltegravir , 2016, The Journal of pharmacy and pharmacology.

[51]  L. Waters,et al.  Iatrogenic Cushing's syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies. , 2016, Clinical medicine.

[52]  M. Egger,et al.  Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population , 2016, Current opinion in HIV and AIDS.

[53]  S. Rannard,et al.  Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy. , 2016, Advanced drug delivery reviews.

[54]  B. Wynne,et al.  The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects , 2016, Journal of acquired immune deficiency syndromes.

[55]  C. Marzolini,et al.  Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. , 2016, The Journal of antimicrobial chemotherapy.

[56]  L. Calza,et al.  Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients. , 2016, The Journal of antimicrobial chemotherapy.

[57]  B. KrentzHartmut,et al.  The Impact of Non-Antiretroviral Polypharmacy on the Continuity of Antiretroviral Therapy (ART) Among HIV Patients , 2016 .

[58]  D. Back,et al.  Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[59]  Mary Jordan Samuel American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults , 2015, Journal of the American Geriatrics Society.

[60]  Richard D Moore,et al.  Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. , 2015, Annals of internal medicine.

[61]  C. Corallo,et al.  Postoperative Bleeding After Administration of a Single Dose of Rivaroxaban to a Patient Receiving Antiretroviral Therapy , 2015, Drug Safety - Case Reports.

[62]  A. Mangoni,et al.  Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis. , 2015, British journal of clinical pharmacology.

[63]  M. Preisig,et al.  Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population , 2015, Open forum infectious diseases.

[64]  T. Hallett,et al.  Future challenges for clinical care of an ageing population infected with HIV: a modelling study , 2015, The Lancet. Infectious diseases.

[65]  C. Fagard,et al.  Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[66]  P. Fulco,et al.  An unexpected interaction between warfarin and cobicistat-boosted elvitegravir. , 2015, AIDS.

[67]  Danijela Gnjidic,et al.  Reducing inappropriate polypharmacy: the process of deprescribing. , 2015, JAMA internal medicine.

[68]  G. Dolci,et al.  Aging with HIV vs. HIV Seroconversion at Older Age: A Diverse Population with Distinct Comorbidity Profiles , 2015, PloS one.

[69]  M. Budoff,et al.  HIV Infection, Cardiovascular Disease Risk Factor Profile, and Risk for Acute Myocardial Infarction , 2015, Journal of acquired immune deficiency syndromes.

[70]  S. Piscitelli,et al.  Pharmacokinetics of Dolutegravir When Administered With Mineral Supplements in Healthy Adult Subjects , 2014, Journal of clinical pharmacology.

[71]  P. Reiss,et al.  Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[72]  M. Goldstein,et al.  Health Outcomes Associated with Polypharmacy in Community‐Dwelling Older Adults: A Systematic Review , 2014, Journal of the American Geriatrics Society.

[73]  Paul Gallagher,et al.  STOPP/START criteria for potentially inappropriate prescribing in older people: version 2 , 2014, Age and ageing.

[74]  M. Winniford,et al.  Impact of Clinical and Therapeutic Factors on Incident Cardiovascular and Cerebrovascular Events in a Population‐Based Cohort of HIV‐Infected and Non–HIV‐Infected Adults , 2014, Clinical cardiology.

[75]  C. Boyd,et al.  Patient-centered care for people living with multimorbidity. , 2014, Current opinion in HIV and AIDS.

[76]  B. Feldt-Rasmussen,et al.  Increased risk of dialysis and end-stage renal disease among HIV patients in Denmark compared with the background population. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[77]  R. Ebrahimi,et al.  Fanconi Syndrome Accompanied by Renal Function Decline with Tenofovir Disoproxil Fumarate: A Prospective, Case-Control Study of Predictors and Resolution in HIV-Infected Patients , 2014, PloS one.

[78]  V. Valcour,et al.  Polypharmacy, Drug–Drug Interactions, and Potentially Inappropriate Medications in Older Adults with Human Immunodeficiency Virus Infection , 2014, Journal of the American Geriatrics Society.

[79]  M. Taljaard,et al.  A cross-sectional, population-based study measuring comorbidity among people living with HIV in Ontario , 2014, BMC Public Health.

[80]  M. Battegay,et al.  Gastrointestinal bleeding associated with rivaroxaban administration in a treated patient infected with human immunodeficiency virus. , 2014, Swiss medical weekly.

[81]  James J. Goedert,et al.  Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada , 2013, PloS one.

[82]  D. Nguyen,et al.  Inhaled corticosteroid use in HIV‐positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management , 2013, HIV medicine.

[83]  A. Mathias,et al.  Pharmacokinetics of Once-Daily Boosted Elvitegravir When Administered in Combination With Acid-Reducing Agents , 2013, Journal of acquired immune deficiency syndromes.

[84]  A. Forrest,et al.  Pharmacokinetics of two common antiretroviral regimens in older HIV‐infected patients: a pilot study , 2013, HIV medicine.

[85]  B. Gazzard,et al.  Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. , 2013, The Journal of antimicrobial chemotherapy.

[86]  Benoit Chauvin,et al.  Drug–Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors , 2013, Clinical Pharmacokinetics.

[87]  J. Chmiel,et al.  Polypharmacy and Risk of Antiretroviral Drug Interactions Among the Aging HIV-Infected Population , 2013, Journal of General Internal Medicine.

[88]  M. Wiese,et al.  Predicted metabolic drug clearance with increasing adult age. , 2013, British journal of clinical pharmacology.

[89]  H. Crauwels,et al.  Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine. , 2013, AIDS reviews.

[90]  Richard D Moore,et al.  Predictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection: A North American Cross Cohort Analysis , 2013, Journal of acquired immune deficiency syndromes.

[91]  K. Dooley,et al.  Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin: Results of a Phase 1 Study Among Healthy Subjects , 2013, Journal of acquired immune deficiency syndromes.

[92]  Danijela Gnjidic,et al.  Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. , 2012, Journal of clinical epidemiology.

[93]  J. Wooten Pharmacotherapy Considerations in Elderly Adults , 2012, Southern medical journal.

[94]  Emily R Hajjar,et al.  Polypharmacy, adverse drug reactions, and geriatric syndromes. , 2012, Clinics in geriatric medicine.

[95]  R. Weber,et al.  Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[96]  R. Weber,et al.  Ageing with HIV: medication use and risk for potential drug-drug interactions. , 2011, The Journal of antimicrobial chemotherapy.

[97]  R. Bertz,et al.  Effect of Low‐Dose Omeprazole (20 mg Daily) on the Pharmacokinetics of Multiple‐Dose Atazanavir With Ritonavir in Healthy Subjects , 2011, Journal of clinical pharmacology.

[98]  R. Hamers,et al.  Interaction between Antiretroviral Drugs and Acenocoumarol , 2011, Antiviral therapy.

[99]  P. Anderson,et al.  Effect of Antacids on the Pharmacokinetics of Raltegravir in Human Immunodeficiency Virus-Seronegative Volunteers , 2010, Antimicrobial Agents and Chemotherapy.

[100]  M. Lederman,et al.  Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. , 2010, AIDS research and human retroviruses.

[101]  V. Sharp,et al.  Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis. , 2009, The AIDS reader.

[102]  P. Fulco,et al.  Possible Antiretroviral Therapy‐Warfarin Drug Interaction , 2008, Pharmacotherapy.

[103]  K. Markides,et al.  Association of Suboptimal Prescribing and Change in Lower Extremity Physical Function over Time , 2008, Gerontology.

[104]  V. Appay,et al.  Immune activation and inflammation in HIV‐1 infection: causes and consequences , 2008, The Journal of pathology.

[105]  Mridula Nair,et al.  Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkable , 2007, Expert opinion on drug safety.

[106]  C. Hughes,et al.  Interaction between lopinavir/ritonavir and warfarin , 2007, Canadian Medical Association Journal.

[107]  C. Fichtenbaum,et al.  Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers , 2005, Clinical pharmacology and therapeutics.

[108]  Stephen H. D. Jackson,et al.  Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. , 2003, British journal of clinical pharmacology.

[109]  D. Singer,et al.  Polypharmacy and medication adherence in patients with type 2 diabetes. , 2003, Diabetes care.

[110]  A. Levy,et al.  Effect of Number of Medications on Cardiovascular Therapy Adherence , 2002, The Annals of Pharmacotherapy.

[111]  J. Avorn,et al.  The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. , 1997, American journal of hypertension.

[112]  C. Flexner,et al.  Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis , 2019, Current opinion in HIV and AIDS.

[113]  M. Boffito,et al.  Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and Cognition , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[114]  M. Núñez-Núñez,et al.  Potential interactions in a cohort of elderly hiv-positive patients. , 2018, Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria.

[115]  A. Mocroft,et al.  Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. , 2016, The lancet. HIV.

[116]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.